Loading...
PAYS logo

Paysign, Inc.NasdaqCM:PAYS 株式レポート

時価総額 US$763.4m
株価
n/a
1Y166.4%
7D7.8%
1D2.1%
ポートフォリオ価値
表示

Paysign, Inc.

NasdaqCM:PAYS 株式レポート

時価総額:US$763.4m

Paysign(PAYS)株式概要

は、プリペイドカード・プログラム、患者向けアフォーダビリティ・サービス、デジタル・バンキング、ライフサイエンス・ソフトウェア・テクノロジー・ソリューション、統合決済処理サービスを、米国の企業、消費者、政府機関に提供している。 詳細

PAYS ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長4/6
過去の実績6/6
財務の健全性6/6
配当金0/6

PAYS Community Fair Values

Create Narrative

See what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

Top Community Narratives

US$43.01
FV
67.9% 割安 内在価値ディスカウント
================================================================================ INTRINSIC VALUE (DCF) CALCULATION BREAKDOWN — NASDAQ:PAYS ================================================================================ Target Fair Value: USD 43.01 Current Stock Price: USD 9.17 Market Assessment: 78.7% Undervalued / +369.1% Upside Potential -------------------------------------------------------------------------------- 1. MARKET METRICS RECONCILIATION -------------------------------------------------------------------------------- * Undervaluation Formula: (Fair Value - Current Price) / Fair Value (43.01 - 9.17) / 43.01 = 0.7868 -> 78.7% * Upside Potential Formula: (Fair Value - Current Price) / Current Price (43.01 - 9.17) / 9.17 = 3.6906 -> +369.1% -------------------------------------------------------------------------------- 2. DISCOUNT RATE / COST OF EQUITY (CAPM) -------------------------------------------------------------------------------- * Formula: Risk-Free Rate + (Beta * Equity Risk Premium) * Inputs: Risk-Free Rate = 4.25% Beta = 1.10 ERP = 5.00% * Calculation: 4.25% + (1.10 * 5.00%) = 4.25% + 5.50% = 9.75% (Rounded to 9.8%) -------------------------------------------------------------------------------- 3. 10-YEAR CASH FLOW FORECAST ARCHITECTURE -------------------------------------------------------------------------------- * Base Year Free Cash Flow (FCF0): USD 70.02M (USD 1.2524 per share) * Shares Outstanding: 55.91m (Market Cap 512.66M / Price 9.17) * FCF Margin: 76.5% * Growth Rate Fading Schedule: - Year 1: +25.00% FCF USD 87.52M - Years 2-10: Linear reduction from +25.00% down to +2.50% - Year 10: +2.50% FCF USD 248.91M - Year 11+: +2.50% (Terminal Perpetual Growth Rate) -------------------------------------------------------------------------------- 4. MATHEMATICAL STEPS TO INTRINSIC VALUE -------------------------------------------------------------------------------- * Step A: Present Value of Discrete Cash Flows (Years 1 to 10) PV_Cash_Flows = Sum [ FCF_t / (1 + 0.0975)^t ] for t = 1 to 10 PV_Cash_Flows = USD 1.02B * Step B: Terminal Value (Gordon Growth Model at Year 10) TV_10 = [ FCF_10 * (1 + 0.0250) ] / (0.0975 - 0.0250) TV_10 = [ 248.91M * 1.0250 ] / 0.0725 = USD 3.52B * Step C: Discount the Terminal Value to Present Day PV_TV = 3.52B / (1 + 0.0975)^10 = 3.52B / 2.5354 PV_TV = USD 1.39B * Step D: Equity Value and Fair Value per Share Equity Value = 1.02B + 1.39B = USD 2.40B Fair Value = 2.40B / 55.91m = USD 43.01 -------------------------------------------------------------------------------- 5. FUTURE P/E MULTIPLE BLENDED BENCHMARK -------------------------------------------------------------------------------- * Formula: Sum of (Multiple * Re-normalized Weight) * Inputs: Forward Multiple: 39.9x @ 45% Weight Peer Median (n=13): 13.8x @ 35% Weight Current Multiple: 53.6x @ 20% Weight * Calculation: (39.9 * 0.45) + (13.8 * 0.35) + (53.6 * 0.20) = 17.941 + 4.817 + 10.719 = 33.477x (Rounded to 33.5x) -------------------------------------------------------------------------------- 6. SENSITIVITY OF THE FAIR VALUE -------------------------------------------------------------------------------- * Growth +22.0% -> 38.38 | +25.0% -> 43.01 | +28.0% -> 43.01 * Discount 8.75% -> 50.72 | 9.75% -> 43.01 | 10.75% -> 37.20 ================================================================================
17
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Paysign, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Paysign
過去の株価
現在の株価US$13.80
52週高値US$13.96
52週安値US$3.08
ベータ0.76
1ヶ月の変化55.41%
3ヶ月変化117.67%
1年変化166.41%
3年間の変化557.14%
5年間の変化452.00%
IPOからの変化2,966.67%

最新ニュース

新しいナラティブ Aug 05

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

Paysign trades below the value implied by discounting its own free cash flow. On a two-stage model running 10 years of +25.0% growth fading to a 2.5% terminal rate, discounted at 9.8%, the shares are worth USD 43.01 against a market price of USD 9.17 — a 79% discount, or +369% to fair value.
ナラティブ更新 Aug 05

PAYS: Share Repurchase And New Pharma Programs Will Support Future Upside

Analysts raised their price target on Paysign to $11, up from a previous range of $8 to $9, citing the updated fair value estimate of $10.45 and the addition of new pharma programs as key factors supporting the change. What’s in the News for Paysign Paysign announced a share repurchase program that authorizes the company to buy back up to US$5 million of its outstanding common stock.

Recent updates

新しいナラティブ Aug 05

5/8/26 — Paysign: trading 79% below a 9.8%-discounted fair value, with the cash flow to defend it

Paysign trades below the value implied by discounting its own free cash flow. On a two-stage model running 10 years of +25.0% growth fading to a 2.5% terminal rate, discounted at 9.8%, the shares are worth USD 43.01 against a market price of USD 9.17 — a 79% discount, or +369% to fair value.
ナラティブ更新 Aug 05

PAYS: Share Repurchase And New Pharma Programs Will Support Future Upside

Analysts raised their price target on Paysign to $11, up from a previous range of $8 to $9, citing the updated fair value estimate of $10.45 and the addition of new pharma programs as key factors supporting the change. What’s in the News for Paysign Paysign announced a share repurchase program that authorizes the company to buy back up to US$5 million of its outstanding common stock.
ナラティブ更新 Jun 24

PAYS: 2026 Earnings Guidance And Margin Outlook Will Support Repricing

Analysts have maintained their $12.75 price target on Paysign, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which together support keeping the current valuation view unchanged. What’s in the News for Paysign Paysign issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$26.2 million to US$26.7 million.
ナラティブ更新 Jun 04

PAYS: Higher 2026 Margin Guidance And P/E Framework Will Support Repricing

Analysts have increased their price target on Paysign by $1 to $12.75, reflecting updated views on its growth, margins, and P/E assumptions. What's in the News Paysign issued earnings guidance for the first quarter of 2026, expecting revenue of US$27.0 million to US$27.5 million, with 137 active patient affordability programs and 589 plasma centers projected at quarter end.
ナラティブ更新 May 20

PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing

Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.
ナラティブ更新 Apr 30

PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions

Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.
ナラティブ更新 Apr 12

PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing

Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.
ナラティブ更新 Mar 28

PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing

The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.
分析記事 Feb 05

The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%

Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...
分析記事 Nov 16

Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next

Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...
Seeking Alpha Oct 01

Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)

Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking Alpha
分析記事 Aug 09

Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...
ナラティブ更新 Aug 07

Digital Payment Solutions Will Expand Healthcare Access Further

Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.
分析記事 May 06

Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings

Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...
分析記事 Mar 04

Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up

With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...
分析記事 Dec 27

Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Seeking Alpha Nov 20

Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth

Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha
User avatar
新しいナラティブ Sep 26

Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures

The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.
分析記事 Sep 07

Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
分析記事 Aug 02

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...
Seeking Alpha Jun 30

Paysign: Expect Rapid Growth In Its Pharma Business

Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking Alpha
分析記事 Apr 26

Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...
分析記事 Mar 29

Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

株主還元

PAYSUS Diversified FinancialUS 市場
7D7.8%0.2%-0.8%
1Y166.4%-0.5%20.5%

業界別リターン: PAYS過去 1 年間で-0.5 % の収益を上げたUS Diversified Financial業界を上回りました。

リターン対市場: PAYS過去 1 年間で20.5 % の収益を上げたUS市場を上回りました。

価格変動

Is PAYS's price volatile compared to industry and market?
PAYS volatility
PAYS Average Weekly Movement10.3%
Diversified Financial Industry Average Movement6.2%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

安定した株価: PAYS 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: PAYSの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
2001226Mark Newcomerwww.paysign.com

Paysign, Inc.は、プリペイドカード・プログラム、患者向けアフォーダビリティ・サービス、デジタル・バンキング、ライフサイエンス・ソフトウェア・テクノロジー・ソリューション、統合決済処理サービスを、米国の企業、消費者、政府機関向けに提供している。同社は、企業報奨金、プリペイドギフトカード、汎用リローダブルデビットカード、従業員インセンティブ、消費者リベート、ドナー報酬、臨床試験、医療費償還支払いと医薬品支払支援、デビットカードとソフトウェアソリューションでアクセス可能な要求払い預金口座などのソリューションを提供している。また、カスタマーサービスセンターを運営し、モバイルアプリ、双方向SMS、テキストアラート、カード会員ポータルなどのコミュニケーションサービスも提供している。プリペイドカード・ソリューションはPaysignのブランド名で販売されている。同社は、報酬、リベート、支払い支援、その他顧客、従業員、代理店などへの支払いソリューションを必要とする企業や自治体にサービスを提供している。は2001年に設立され、ネバダ州ヘンダーソンに本社を置いている。

Paysign, Inc. 基礎のまとめ

Paysign の収益と売上を時価総額と比較するとどうか。
PAYS 基礎統計学
時価総額US$763.37m
収益(TTM)US$15.77m
売上高(TTM)US$100.64m
49.4x
PER(株価収益率
7.7x
P/Sレシオ

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
PAYS 損益計算書(TTM)
収益US$100.64m
売上原価US$39.26m
売上総利益US$61.39m
その他の費用US$45.61m
収益US$15.77m

直近の収益報告

Jun 30, 2026

次回決算日

該当なし

一株当たり利益(EPS)0.28
グロス・マージン61.00%
純利益率15.67%
有利子負債/自己資本比率0%

PAYS の長期的なパフォーマンスは?

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/08/19 04:44
終値2026/08/19 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Paysign, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6

アナリスト機関
Gary PrestopinoBarrington Research Associates, Inc.
Austin MoldowCanaccord Genuity
Peter HeckmannD.A. Davidson & Co.